To march in or not to march in.

Suppr

超能文献

作者信息

Black C Allen

出版信息

Nat Med. 2011 Aug 4;17(8):921; author reply 921-2. doi: 10.1038/nm.2440.

DOI:10.1038/nm.2440

PMID:21818082

Abstract

摘要

相似文献

To march in or not to march in.

Nat Med. 2011 Aug 4;17(8):921; author reply 921-2. doi: 10.1038/nm.2440.

March on, not in.

Nat Med. 2011 May;17(5):515. doi: 10.1038/nm0511-515.

NIH faces marching orders on orphan drug shortage.

Nat Med. 2011 May;17(5):522. doi: 10.1038/nm0511-522b.

[Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].

Presse Med. 2010 May;39(5):527-9. doi: 10.1016/j.lpm.2010.01.002. Epub 2010 Mar 2.

The Fabrazyme shortage--a call to action for metabolic physicians.

Mol Genet Metab. 2011 Jan;102(1):4-5. doi: 10.1016/j.ymgme.2010.11.002. Epub 2010 Dec 15.

Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).

Mol Genet Metab. 2011 Jan;102(1):99-102. doi: 10.1016/j.ymgme.2010.11.155. Epub 2010 Nov 30.

Clinical trial for Fabry disease faces continuing hurdles.

CMAJ. 2009 Nov 24;181(11):E251-2. doi: 10.1503/cmaj.109-3071. Epub 2009 Oct 13.

Drug shortages and public health.

N Engl J Med. 2009 Oct 15;361(16):1525-7. doi: 10.1056/NEJMp0906922.

A united front.

Nature. 2011 Apr 28;472(7344):389-90. doi: 10.1038/472389b.

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.

Orphanet J Rare Dis. 2011 Oct 31;6:69. doi: 10.1186/1750-1172-6-69.

引用本文的文献

Debates over orphan drug pricing: a meta-narrative literature review.

Orphanet J Rare Dis. 2025 Mar 7;20(1):107. doi: 10.1186/s13023-025-03634-2.

本文引用的文献

Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).

Mol Genet Metab. 2011 Jan;102(1):99-102. doi: 10.1016/j.ymgme.2010.11.155. Epub 2010 Nov 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

To march in or not to march in.

Nat Med. 2011 Aug 4;17(8):921; author reply 921-2. doi: 10.1038/nm.2440.

March on, not in.

Nat Med. 2011 May;17(5):515. doi: 10.1038/nm0511-515.

NIH faces marching orders on orphan drug shortage.

Nat Med. 2011 May;17(5):522. doi: 10.1038/nm0511-522b.

[Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].

Presse Med. 2010 May;39(5):527-9. doi: 10.1016/j.lpm.2010.01.002. Epub 2010 Mar 2.

The Fabrazyme shortage--a call to action for metabolic physicians.

Mol Genet Metab. 2011 Jan;102(1):4-5. doi: 10.1016/j.ymgme.2010.11.002. Epub 2010 Dec 15.

Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).

Mol Genet Metab. 2011 Jan;102(1):99-102. doi: 10.1016/j.ymgme.2010.11.155. Epub 2010 Nov 30.

Clinical trial for Fabry disease faces continuing hurdles.

CMAJ. 2009 Nov 24;181(11):E251-2. doi: 10.1503/cmaj.109-3071. Epub 2009 Oct 13.

Drug shortages and public health.

N Engl J Med. 2009 Oct 15;361(16):1525-7. doi: 10.1056/NEJMp0906922.

A united front.

Nature. 2011 Apr 28;472(7344):389-90. doi: 10.1038/472389b.

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.

Orphanet J Rare Dis. 2011 Oct 31;6:69. doi: 10.1186/1750-1172-6-69.

引用本文的文献

Debates over orphan drug pricing: a meta-narrative literature review.

Orphanet J Rare Dis. 2025 Mar 7;20(1):107. doi: 10.1186/s13023-025-03634-2.

本文引用的文献

Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).

Mol Genet Metab. 2011 Jan;102(1):99-102. doi: 10.1016/j.ymgme.2010.11.155. Epub 2010 Nov 30.